Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory ...
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced positive results from the chronic period of the TUSCANY-2 Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results